Response Genetics, Inc. Appoints John Ferrara to Its Board of Directors

Response Genetics, Inc. (NASDAQ: RGDX), a company focused on the
development of molecular diagnostic tests for cancer, announced today
that John C. Ferrara has joined its Board of Directors.

Mr. Ferrara is currently the Chief Financial Officer (CFO) for
EDGAR(R) Online(R), Inc. (NASDAQ: EDGR) a leading provider of
value-added business and financial information on global companies to
financial, corporate and advisory professionals. Prior to joining
EDGAR Online, Mr. Ferrara served as Interim CFO to GAMCO Investors

Inc., President of The LGL Group, Inc. and has held CFO positions at
Space Holding Corporation, Golden Books Family Entertainment and
Renaissance Communications Corporation.

Since 1999, Mr. Ferrara has served on the Board of Directors of
several public companies, including GAMCO Investors and Lynch
Interactive. Mr. Ferrara holds a B.S. in Accounting from the
University of Maryland and an M.B.A. in Finance from Columbia
University.

"Response Genetics is pleased to welcome John Ferrara as a new
member on our Board of Directors," said Kathleen Danenberg, CEO and
President of Response Genetics, Inc. "John´s extensive financial
experience expands the depth and breadth of Response Genetics´ board.
We look forward to his involvement and contributions to the Company."

Mr. Ferrara´s tenure on the Board commenced April 4, 2008.

About Response Genetics, Inc.

Response Genetics, Inc. ("RGI") (the "Company") (NASDAQ: RGDX) is
engaged in the research and development of pharmacogenomic cancer
diagnostic tests based on its proprietary and patented technologies.
RGI´s technologies enable extraction and analysis of genetic
information from genes derived from tumor samples stored as
formalin-fixed and paraffin embedded specimens. RGI currently
generates revenue primarily from the sales of its proprietary
analytical pharmacogenomic testing services of clinical trial
specimens to the pharmaceutical industry. The Company was founded in
1999 and its principal headquarters are located in Los Angeles

California. For more information, please visit
www.responsegenetics.com.

Forward Looking Statement Notice

Except for the historical information contained herein, this press
release and the statements of representatives of RGI related thereto
contain or may contain, among other things, certain forward-looking
statements, within the meaning of the Private Securities Litigation
Reform Act of 1995.

Such forward-looking statements involve significant risks and
uncertainties. Such statements may include, without limitation

statements with respect to the Company´s plans, objectives

projections, expectations and intentions, such as the ability of the
Company to analyze cancer samples, the potential for using the results
of this research to develop diagnostic tests for cancer, the
usefulness of genetic information to tailor treatment to patients, the
ability of the Company to make its ResponseDx:Lung(TM) and
ResponseDX:Colon(TM) tests available in a number of institutions, and
other statements identified by words such as "projects," "may,"
"could," "would," "should," "believes," "expects," "anticipates,"
"estimates," "intends," "plans" or similar expressions.

These statements are based upon the current beliefs and
expectations of the Company´s management and are subject to
significant risks and uncertainties, including those detailed in the
Company´s filings with the Securities and Exchange Commission. Actual
results, including, without limitation, actual sales results, if any

or the application of funds, may differ from those set forth in the
forward-looking statements. These forward-looking statements involve
certain risks and uncertainties that are subject to change based on
various factors (many of which are beyond the Company´s control). The
Company undertakes no obligation to publicly update forward-looking
statements, whether because of new information, future events or
otherwise, except as required by law.